Goldman Sachs’s Correvio Pharma Corp. Ordinary Shares (Canada) CORV Stock Holding History

Goldman Sachs’s Portfolio CORV Stock Details CORV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-12,274	Closed	-$49K	–	5877
2018 Q3	$49K	Buy	+12,274	New	+$54.1K	﹤0.01%	5296
2016 Q4	–	Sell	-11,007	Closed	-$34K	–	7188
2016 Q3	$34K	Sell	11,007 -187	-2%	-$682	﹤0.01%	6609
2016 Q2	$57K	Buy	+11,194	New	+$53.8K	﹤0.01%	6385
2015 Q2	–	Sell	-12,642	Closed	-$117K	–	7539
2015 Q1	$117K	Buy	+12,642	New	+$121K	﹤0.01%	6364

Other funds holding CORV

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

CCP

Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return

Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

AIP

ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs's CORV Position: Q4 2018 in Review

Goldman Sachs sold out of Correvio Pharma Corp. Ordinary Shares (Canada) (CORV) in Q4 2018, closing a stake of 12,274 shares — an estimated $49K sold.

Goldman Sachs first reported a position in CORV in Q1 2015 and held it in 4 quarters. The position peaked at $117K in Q1 2015. 36 funds tracked by Wall St. Rank hold CORV as of Q4 2018.

Goldman Sachs reported no remaining Correvio Pharma Corp. Ordinary Shares (Canada) position as of Q4 2018 after selling out during the quarter.
Goldman Sachs sold 12,274 Correvio Pharma Corp. Ordinary Shares (Canada) shares in Q4 2018, an estimated $49K.
Goldman Sachs first reported a position in Correvio Pharma Corp. Ordinary Shares (Canada) in Q1 2015 and held it in 4 quarters.
Goldman Sachs's Correvio Pharma Corp. Ordinary Shares (Canada) position peaked at $117K in Q1 2015.
36 funds tracked by Wall St. Rank held Correvio Pharma Corp. Ordinary Shares (Canada) as of Q4 2018.

Based on Goldman Sachs's 13F filing for Q4 2018, filed 14 Feb 2019.